参考文献

［1] SEMSARIAN C，INGLES J，MARON M S，et al. New perspectives on the prevalence of hypertrophic cardiomyopathy［J］. J Am Coll Cardiol，2015，65（12）：1249-1254.

［2] SPIRITO P，SEIDMAN C E，MCKENNA W J，et al. The management of hypertrophic cardiomyopathy［J］. N Engl J Med，1997，336（11）：775-785.

［3] SHIRANI J，PICK R，ROBERTS W C，et al. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death［J］. J Am Coll Cardiol，2000，35（1）：36-44.

［4] ELLIOTT P M，ANASTASAKIS A，BORGER M A，et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy：the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology（ESC）［J］. Eur Heart J，2014，35（39）：2733-2779.

［5] 中国医师协会心力衰竭专业委员会，中华心力衰竭和心肌病杂志编辑委员会.中国肥厚型心肌病管理指南2017［J］.中华心力衰竭和心肌病杂志，2017，1（2）：65.

［6] MARON M S，OLIVOTTO I，BETOCCHI S，et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy［J］.N Engl J Med，2003，348（4）：295-303.

［7] OMMEN S R，MARON B J，OLIVOTTO I，et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy［J］. Digest World Core Med J，2005，46（3）：470-476.

［8] WANG S，CUI H，YU Q，et al. Excision of anomalous muscle bundles as an important addition to extended septal myectomy for treatment of left ventricular outflow tract obstruction［J］. J Thorac cardiovasc Surg，2016，152（2）：461-468.

［9] SIGWART U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy［J］. Lancet，1995，346（8969）：1624.

［10] FABER L，SEGGEWISS H，GLEICHMANN U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy：results with respect to intraprocedural myocardial contrast echocardiography［J］. Circulation，1998，98（22）：2415-2421.

［11] LIEBREGTS M，VRIESENDORP P A，MAHMOODI B K，et al. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy［J］. JACC Heart fail，2015，3（11）：896-905.

［12] MARON B J，MARON M S，WIGLE E D，et al. The 50-year history，controversy，and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy：from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy［J］. J Am Coll Cardiol，2009，54（3）：191-200.

［13] CROSSEN K，JONES M，ERIKSON C. Radiofrequency septal reduction in symptomatic hypertrophic obstructive cardiomyopathy［J］. Heart rhythm，2016，13（9）：1885-1890.

［14] LIU L，LI J，ZUO L，et al. Percutaneous intramyocardial septal radiofrequency ablation for hypertrophic obstructive cardiomyopathy［J］. J Am Coll Cardiol，2018，72（16）：1898-1909.

［15] 刘丽文，左蕾，周梦垚，等. 经胸超声心动图引导下经皮心肌内室间隔射频消融术治疗梗阻性肥厚型心肌病的安全性和有效性［J］. 中华心血管病杂志，2019，47（4）：284-290.

［16] MARON B J，NISHIMURA R A，MCKENNA W J，et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized，double-blind，crossover study（M-PATHY）［J］. Circulation，1999，99（22）：2927-2933.

［17] NISHIMURA R A，TRUSTY J M，HAYES D L，et al. Dual-chamber pacing for hypertrophic cardiomyopathy：a randomized，double-blind，crossover trial［J］. J Am Coll Cardiol，1997，29（2）：435-441.

［18] QINTAR M，MORAD A，ALHAWASLI H，et al. Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy［J］.Cochrane database Sys Rev，2012（5）：Cd008523.

［19] GERSH B J，MARON B J，BONOW R O，et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy：executive summary：a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines［J］. Circulation，2011，124（24）：2761-2796.

［20] GUTTMANN O P，RAHMAN M S，O'MAHONY C，et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy：systematic review［J］. Heart，2014，100（6）：465-472.

［21] PELLICCIA A，FAGARD R，BJ RNSTAD H H，et al. Recommendations for competitive sports participation in athletes with cardiovascular disease：a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myo［J］. Acc Current J Rev，2005，14（11）：6.

［22] WEINSTOCK J，BADER Y H，MARON M S，et al. Subcutaneous implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy：An initial experience［J］. J Am Heart Assoc，2016，5（2）：e002488.